Efficacy of Combination Therapy of Clindamycin and Rifampicin in Recurrent Furunculosis

Abstract

Objective To assess the efficacy of combination therapy of clindamycin and rifampicin in recurrent furunculosis.   Methods This study was conducted at the outpatient Department of Dermatology (Khalifa Gul Nawaz teaching hospital MTI, Bannu, Bannu Medical College) from December 2019 to December 2020. A total of 150 patients aged between 18 and 65 years of recurrent furunculosis were enrolled. Mupirocin 2 percent was applied on the lesions involving the nostrils, and anal region twice daily, and took oral 400mg tablet of metronidazole three times daily for 10 days. They were prescribed Clindamycin 300 mg twice daily and Rifampicin 600 mg OD for 10 days. The drug is considered efficacious if the patient had no episode of furuncles during a 2-3 month followâ€up period.   Results There were 74 patients in Group A and 76 in Group B. Patients in Groups A and B had 30 (40.54%) and 46 (60.52%) male patients and 44 (59.45%) and 30 (39.47%) female patients, respectively. Patients had five major sites of disease recurrence; face 31 (20.6%), neck 30 (20%), axilla 32 (21.3%), buttock 36 (24%) and groin in 21 (14%) patients.   Conclusion It is concluded that combination therapy of clindamycin and Rifampicin in recurrent furunculosis is far better than a patient receiving no treatment for recurrent furunculosis. So, combination therapy of Clindamycin and Rifampicin should be considered a promising alternative for treating recurrent furunculosis.   Key words Clindamycin, rifampicin, recurrent furunculosis.